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ABBREVIATIONS AND ACRONYMS 
 
 
RHD -  RHEUMATIC HEART DISEASE 
MS  - MITRAL STENOSIS 
MR - MITRAL REGURGITATION  
SR - SINUS RHYTHM 
AF - ATRIAL FIBRILLATION  
AS - AORTIC STENOSIS 
AR - AORTIC REGURGITATION 
LAA  - LEFT ATRIAL APPENDAGE 
TTE - TRANS THORACIC ECHOCARDIOLOGY 
MVA - MITRAL VALVE AREA. 
LA    -        LEFT ATRIUM 
 
INTRODUCTION 
In spite of tremendous and advanced improvement both in 
preventive aspects as well as therapeutic part Rheumatic Heart Disease 
forms a part of health hazard in developing countries.  A part of 
complication of RHD puts these patients for a major morbidity leading to 
mortality.  So this preventable complication i.e. thromboembolic 
manifestation to a extent can be predicted, and it is taken as my study. 
 
 This study based on plasma D-dimer levels and predicting a major 
adverse event, thromboembolic manifestation in these patients.  Plasma 
D-dimers are cross linked fibrin derivatives which result from 
degradation of fibrin by endogenous fibrinolytic system. 
 
They reflect both increased coagulation and an active fibrinolytic 
system and are markers for clot risk. 
 
 
AIMS AND OBJECTIVES 
 Assessing prothrombotic burden in patients with Rheumatic heart 
diseases with AF or without AF using plasma D-dimer levels and 
comparing the D-dimer levels among the Rheumatic heart disease 
patients with various subsets of patients. 
 
 Correlation of AF to left atrial size and to age and to D-dimer level 
in the study sample. 
                                                                                                                                                            
 Correlation of mitral regurgitation to D-dimer level as a part of 
systemic hypo fibrinolytic state. 
 
  Correlating left atrial empting velocity to D-dimer level as a part of 
Intra atrial hemodynamics.  
 
 
 
REVIEW OF LITERATURE 
Plasma D-dimers 
Plasma D-dimers are cross linked fibrin derivatives which result 
from the degradation of fibrin by the endogenous fibrinlytic system(1).  
They reflect both increased systemic coagulation and an active 
fibrinolytic system, and are markers for thromboembolic risk(2,3,4).      
D-dimer is a fibrin degradation product (or FDP), a small protein 
fragment present in the blood after a blood clot is degraded 
by fibrinolysis. It is so named because it contains two crosslinked D 
fragments of the fibrinogen protein.  
D-dimer concentration may be determined by a blood test to help 
in diagnosing thrombosis. Since its introduction in the 1990s, it has 
become an important test performed in patients suspected of thrombotic 
disorders. While a negative result practically rules out thrombosis, a 
positive result can indicate thrombosis but does not rule out other 
potential causes. Its main use, therefore, is to exclude thromboembolic 
disease where the probability is low. In addition, it is used in the 
diagnosis of the blood disorder, disseminated intravascular coagulation.  
 
  
Coagulation, the formation of a blood clot or thrombus, occurs 
when the proteins of the "coagulation cascade" are activated, either by 
contact with damaged blood vessel wall (intrinsic pathway) or by 
activation offactor VII by tissue activating factors. Both pathways lead to 
the generation of thrombin, an enzyme that turns the soluble blood 
protein fibrinogen into fibrin, which aggregates into proteofibrils. 
Another thrombin-generated enzyme, factor XIII, then crosslinks the 
fibrin proteofibrils at the D fragment site, leading to the formation of an 
insoluble gel which serves as a scaffold for blood clot formation.  
The circulating enzyme plasmin, the main enzyme of fibrinolysis, 
cleaves the fibrin gel in a number of places. The resultant fragments, 
"high molecular weight polymers", are digested several times more by 
plasmin to lead to intermediate and then to small polymers (fibrin 
degradation products or FDPs). The cross-link between two D fragments 
remains intact, however, and these are exposed on the surface when the 
fibrin fragments are sufficiently digested. The typical D-dimer containing 
fragment contains two D domains and one E domain of the original 
fibrinogen molecule. 
D-dimers are not normally present in human blood plasma, except 
when the coagulation system has been activated, for instance because of 
the presence of thrombosis or disseminated intravascular coagulation. 
The D-dimer assay depends on the binding of a monoclonal antibody to a 
particular epitope on the D-dimer fragment. Several detection kits are 
commercially available; all of them rely on a different monoclonal 
antibody against D-dimer. Of some of these it is known to which area on 
the D-dimer the antibody binds. The binding of the antibody is then 
measured quantitatively by one of various laboratory methods.  
D-dimer testing is of clinical use when there is a suspicion of deep 
venous thrombosis (DVT), pulmonary embolism (PE) or disseminated 
intravascular coagulation (DIC). It can also rise postoperatively. It is 
under investigation in the diagnosis of aortic dissection.  
For DVT and PE, there are various scoring systems that are used to 
determine the clinical probability of these diseases; the best-known were 
introduced by Wells et al For a very high score, or pretest probability, a 
D-dimer will make little difference and anticoagulant therapy will be 
initiated regardless of test results, and additional testing for DVT or 
pulmonary embolism may be performed.  
`For a moderate or low score, or pretest probability:  
     A negative D-dimer test will virtually rule out thromboembolism: 
the degree to which the D-dimer reduces the probability of thrombotic 
disease is dependent on the test properties of the specific test used in the 
clinical setting: most available D-dimer tests with a negative result will 
reduce the probability of thromboembolic disease to less than 1% if the 
pretest probability is less than 15-20% 
If the D-dimer reads high, then further testing (ultrasound of the leg 
veins or lung scintigraphy or CT scanning) is required to confirm the 
presence of thrombus. Anticoagulant therapy may be started at this point 
or withheld until further tests confirm the diagnosis, depending on the 
clinical situation. 
In some hospitals, they are measured by laboratories after a form is 
completed showing the probability score and only if the probability score 
is low or intermediate. This would reduce the need for unnecessary tests 
in those who are high-probability.  
Various kits have a 93-95% sensitivity and about 50% specificity in the 
diagnosis of thrombotic disease.  
1) False positive readings can be due to various causes: liver disease, 
high rheumatoid 
factor, inflammation, malignancy, trauma, pregnancy, 
recent surgery as well as advanced age 
2) False negative readings can occur if the sample is taken either too 
early after thrombus formation or if testing is delayed for several 
days. Additionally, the presence of anti-coagulation can render the 
test negative because it prevents thrombus extension. 
3) Likelihood ratios are derived from sensitivity and specificity to 
adjust pretest probability. 
4)  D-dimer was originally described in the 1970s, and found its 
diagnostic application in the 1990s.  
 
ATRIAL FIBRILLATION  AND MITRAL STENOSIS  
 Atrial fibrillation (AF) and mitral stenosis (MS) especially in 
combination, increase the risk of left atrial thrombus formation and 
systemic embolization(5). Both, AF and MS cause the stagnation of blood 
in the left atrium, which in turn causes rouleaux formation of the red 
blood cells that is observed as echocardiographic “spontaneous echo 
contrast”  and intracardiac thrombosis(6,7,8,9,10,11,12) . The blood flow 
and endoluminal shear stresses presumably must be below a critical value 
in order to form  intra cardiac SEC and thrombus formation to occur.  
Atrial fibrillation (AF) is the most common sustained arrhythmia in 
the world, occurring in approximately 0.4% of the general population. 
The prevalence of AF increases with age, affecting upto 5% of the 
population over the age of 69 years. 
AF is most commonly associated with advanced age, hypertension, 
valvular heart disease, congestive cardiac failure and coronary artery 
disease. It has also been associated with physiological stress, drugs, 
pulmonary embolism, chronic lung disease, hyperthyroidism, caffeine, 
infections and various metabolic disturbances. Other less common 
cardiac associations include Wolf-Parkinsonism White syndrome. 
Pericarditis and cardiomyopathy. 
AF due to progressive dilation of the left atrium in mitral stenosis 
is very common; its onset precipitates pulmonary edema. Less than 20% 
of the patients remain in sinus rhythm, which is often associated with a 
small fibrotic left atrium and severe pulmonary hypertension. All patients 
are predisposed to left atrial thrombus and systemic thromboembolism 
previously account for  25% of all deaths in this condition, when 
anticoagulation therapy had not been available.       
      Plasma D-dimers are cross-linked fibrin derivatives which result 
from the degradation of fibrin by the endogenous fibrinolytic system.  
They reflect both increased systemic coagulation (thrombogenesis) and 
an active fibrinolytic system, and are markers for thromboembolic risk.  
      
 
 
LEFT ATRIUM  
 The LA fulfills 3 major physiologic roles that impact on LV filling 
and performance.   The LA acts as a contractile pump that delivers 15% 
to 30%  of the LV filling, as a reservoir that collects pulmonary venous 
return during ventricular systole, and as a conduit for the passage of 
stored blood from the LA to the LV during early ventricular diastole.         
Increased LA size is associated with adverse cardiovascular outcomes.                
An increase in atrial size most commonly is related to increase wall 
tension as a result of increased filling pressure.  Although increased 
filling volumes can cause an increase in LA size, the adverse outcomes 
associated with increased dimension and volumes are more strongly 
associated with increased filling pressure.  Relationships exist between 
increased LA size and the incidence of atrial fibrillation and stroke.  LA 
enlargement is a marker of both the severity and chronicity of diastolic 
dysfunction and magnitude of LA pressure elevation.  The LA size is 
measured at the end-ventricular systole when the LA chamber is at its 
greatest dimension. 
LA LINEAR DIMENSION 
     The LA can be visualized from multiple echocardiographic views 
from which several potential LA dimensions can be measured.  However, 
the large volume of prior clinical and research work used with M-mode or 
2D anterio- posterior (AP) linear dimension obtained from the parasternal 
long axis view, making this as standard for linear LA measurement.  The 
convention for M-mode measurement is to measure from the leading edge 
of the posterior aortic wall to the leading edge of the posterior LA wall.  
However, to avoid the variable extent of space between the LA and aortic 
root, the trailing edge of the posterior aortic wall is recommended.          
LAA FLOW IN ATRIAL FIBRILLATION  
Active LAA flow is commonly observed in patients with AF with 
alternating positive and negative sawtooth-appearing flow signals of 
variable amplitude and regularity. Mean LAA flow velocities have 
greater physiologic significance than peak velocities.  These should be 
averaged for each cardiac cycle and then averaged for several cycles.   
Generally, flow velocities during AF are lower than those during sinus 
rhythm.  However, flow velocities in patients with AF are highly variable, 
with high velocity flows on one end of the spectrum (velocities similar to 
or even exceeding, those observed in sinus rhythm,) and minimal to 
absent flow on the other end.  This represents the wide continuum of 
LAA contractile contraction to complete paralysis of the appendage. Of 
mitral and Aortic valve disorders, rheumatic mitral stenosis is most 
commonly associated with thromboembolism, irrespective of co-
existence of MR. AF increase the risk thromboembolism upto 18 times, 
thrombi associated with MS can be found on either the atrial wall or in its 
appendage.  The Risk of thromboembolism in rheumatic valve stenosis is 
related to age and low cardiac output, yet it does not correlate well with 
left atrial size, mitral calcification or severity of mitral stenosis. The 
Association of MR with thromboembolism correlates with the co-
existence of MS.    
ROLE OF DRUGS 
     Oral anticoagulant reduces risk of stroke in patients with rheumatic 
mitral stenosis particularly those with co-existent atrial fibrillation.  Pre 
risk – benefit ratio in those without AF is not known.  The Benefit of 
antiplatelet agents in the prevention of stroke in patients with any type of 
Rheumatic valvular disease has not established.  Of those patients who 
have had one events, early Recurrent embolism has been reported in upto 
two thirds and aggressive anticoagulation instituted. 
MITRAL VALVE DISEASE AND LAA FLOW 
 Hemodynamically significant mitral stenosis increase the resistance 
to both active and passive LAA emptying, resulting in an overall 
lowering of LAA flow regardless of the specific rhythm.  Hwang et 
al(13). Have demonstrated a marked decrease in LAA contraction 
velocities in patients with mitral stenosis, compared with patients without 
rheumatic heart disease, both in sinus rhythm and in AF.  In addition to 
overall important of LAA function, mitral stenosis specifically limits the 
normal augmentation of LAA flow during diastole in patient with AF, a 
phenomenon related to the severity of the stenosis.  In the presence of 
AF, patients with severe mitral stenosis typically demonstrate low-to-
absent LAA velocities.  This is in contrast to nonrhemuatic AF, which is 
associated with a wide spectrum of flow velocities, with both “high 
velocity”.  These effects of mitral stenosis on LAA function are probably 
the result of the severe hemodynamic impairment in patients with mitral 
stenosis. Direct LA and LAA involvement in the rheumatic inflammatory 
process, and an atrial myopathy resulting from chronic LA pressure 
elevation, are additional possibilities. Hemodynamically significant mitral 
regurgitation is predicted to impair LAA function via LA and LAA 
dilatation and increased filling pressure.  Despite a possible deleterious 
effect of mitral regurgitation on LAA function, mitral regurgitation has an 
overall protective effect against thromboembolism by prevention of LA 
stasis. 
     Many studies have suggested that determination of LAA function by 
echocardiography allows the identification of patients with AF or AFL 
who are at high risk for the development of LA or LAA thrombi and 
thromboembolic complications.   
  Cardiogenic embolism accounts for ≥15% of ischemic strokes.  
Left atrial appendage (LAA) thrombi are believed for be the source of 
embolic in a substantial number of these patient, primarily in association 
with atrial fibrillation (AF) or rheumatic mitral valve disease.  Despite the 
blind cul-de-sac and multiple anatomic structure of the LAA, thrombus 
formation is normally prevented by vigorous blood flow in the appendage 
cavity.  Nevertheless, LAA dysfunction in various pathophysiologic state 
may predispose to local thrombosis and systemic embolization. 
 PATHOPHYSIOLOGY OF LAA FUNCTION 
 Age-associated changes in LAA velocities have been described. 
Aging was associated with a progressive linear decline in all LAA flow 
variables (LAA contraction and filling velocities and early diastolic LAA 
flow). A possible effect of various systemic diseases   (e.g., hypertension) 
on LAA function has not been determined. 
 
ECHOCARDIOGRAPHIC CORRELATES.  
1) LA/LAA size: in patients with sinus rhythm, there is no clear 
association between LA size and LAA flow velocities (15). However, 
concomitant LAA enlargement and low LAA contraction velocities are 
common in patients with mitral stenosis who are in sinus rhythm. In 
patients with AF, larger LA and LAA sizes commonly are associated with 
lower LAA flow velocities(16,17,18), both in patients with and in those 
without  associated rheumatic mitral disease. This is most pronounced in 
patients with near absence of LAA flow, in whom significant dilation of 
the LA and LAA is the rule. Of note, significant LAA dilation resulting 
from any cause may potentially further impair LAA function by 
increasing LAA wall stress. 
2) LAA flow versus mitral and pulmonary venous flow: 
The following correlations were observed between LAA flow velocities 
and mitral inflow and pulmonary venous flow velocities in the presence 
of sinus rhythm:  
a) Lack of correlation (19) or even a negative correlation 
    between LAA contraction velocities and mitral inflow A  
      velocities, 
 b) Lack of correlation between LAA and pulmonary 
       venous flow velocities, and  
  c) Significant positive 
Correlation between early diastolic LAA outflow and both mitral E 
velocities and pulmonary venous diastolic velocities, all of which decline 
progressively with aging due to age-related slowing of LV relaxation. 
LAA function versus global LA function.  
  Various methods developed to evaluate LA contractile function are 
time-consuming and, thus, not routinely used in clinical practice. Hence, 
it is tempting to apply LAA flow variables as clinically applicable 
surrogates for global LA function(20,21), although the validity of such an 
approach is questionable. The LAA and main LA cavity are derived 
embryologically from different sources. The trabecular LAA is a remnant 
of the embryonic LA, whereas the smooth LA cavity is derived from an 
outgrowth of the pulmonary veins. Therefore, it is conceivable that LAA 
function may dissociate from global LA function. The following 
arguments support this: 
1) Dissociation of LAA and LA function has been anecdotally reported 
during sinus rhythm in patients with preserved global LA function 
(manifested as normal mitral inflow A velocities), but low or absent LAA 
flow velocities, in association with LAA thrombus formation, 
spontaneous echocardiographic contrast and clinical embolic events.  
2) Dissociation of LA and LAA mechanical activity has been described 
recently in patients after cardioversion, in whom organized LA 
mechanical activity may be present along with disorganized LAA 
contraction. 
LAA FUNCTION BY DOPPELER 
     The LAA has been imaged primarily by transthoracic 
echocardiography (parasternal short-axis view of the base of the heart or 
apical two chamber view). 
1) LAA view- The view with the optimal alignment of Doppler with LAA 
flow, as determined by colour flow imaging, should be selected.  No 
differences in Doppler velocities have been noted using various LAA 
views (22, 23). 
 2) Sample volume location-Currently, there is no standard sampling site 
in the appendage (i.e., sampling at the LAA-LA junction versus sampling 
at different sites within the LAA cavity). It is unclear whether variations 
in sampling site location produce significant changes in measured 
velocities, as demonstrated for other Doppler measurements such as 
mitral inflow velocities (24). In a recent report, a small trend was 
observed for lower velocities at the wider orifice of the LAA, in 
comparison with velocities obtained at the narrower middle portion of the 
appendage (25). LAA flow should be sampled at the site of maximal flow 
velocities (determined by color flow imaging), while avoiding wall 
motion Doppler artifacts, which are commonly observed in the more 
distal (narrow) portions of the appendage. In practice, technically 
adequate tracings of maximal LAA flow velocities are commonly 
recorded within the proximal third of the appendage. 
3) Doppler sample size and machine gains-These are set to visualize a 
spectral Doppler signal with a clear envelope, typical of the normal 
laminar appendage flow. Initially, filters are set at low values to enable 
visualization of low velocity flow, characteristic of early diastolic LAA 
flow in sinus rhythm and LAA flow in a subset of patients with AF. 
METHODOLOGY 
PATIENTS 
 The study population included ‟65‟ patients who are consecutive 
samples coming to our OPD and patients who are admitted in our ward.  
Rheumatic mitral valve disease was diagnosed by the presence of any 
senotic & regurgitation seen in at least two planes by Doppler 
echocardiography, and accompanied by at least two of the following three 
morphological abnormalities of the regurgitant valve:  restricted leaflet 
mobility; focal or generalized valvular thickening; and abnormal 
subvalvular thickening.  In order to provide a definite diagnosis of 
rheumatic heart disease, these features had to be identified concordantly 
by each of the echocardiographers, all of whom were experienced in the 
diagnosis and treatment of rheumatic heart disease 
Exclusion criteria 
 1) Patients aged > 60 years,  
2) With any history of surgery  
3) Acute coronary syndrome during the past 12 weeks 
4) On anticoagulation medications   
5) Also who had a history of stroke  
6) Systemic thromboembolism,  
7) Deep venous throumbus,  
8) Intracardiac thrombus on transthoracic echocardiography,  
9) Uncontrolled hypertension,  
10) Left ventricular systolic failure with ejection fraction < 40%,  
11) Any disease related to and acute phase reaction (acute 
infection, malignancy, end-stage liver disease or chronic renal 
failure (creatinine clearance <35 ml/min or diabetes) were 
excluded from the study.  
           12) Any subjects with a recent history of trauma or surgery were 
  also excluded. 
13) Those patients receiving aspirin stopped their medication five 
         days before venous blood samples were obtained.  
14) Patients in chronic AF were not receiving warfarin secondary 
      to any contraindication, non-compliance or personal preference.   
15) Patients with non-rheumatic causes of MR were not enrolled   
        into the study.  
 All patients provided their informed consent to participate in the 
study, which was approved by the institutional ethical committee. 
INCLUSION CRITERIA: 
1. All patients with RHD with mitral valve and aortic valve 
disease. 
2. Age less than 60 yrs. 
3. Rheumatic heart disease patients in sinus rhythm and in Atrial 
fibrillation. 
 
Echocardiographic examinations 
 Transthoracic echocardiography examinations were performed 
using a 3.5mHz sector transducer with Esaote my lab 5000 
echocardiography system.  The mitral valve area (MVA) was calculated 
using planimetry and pressure half –time methods; MS was defined as 
Mild, Moderate, Severe, by both method.  Mitral regurgitation was 
classified as mild MR (jet area <4 cm
2
), moderate (2D MR jet area 4-
8cm
2
) or severe (2D MR jet area >8 cm
2
).  Eccentric MR jets were 
classified as severe when a pulmonary venous systolic reverse flow was 
detected with Doppler examination. All echocardiographic examinations 
done using TTE with patients in the left lateral decubitus position with 
esaote system.  The transducer was placed somewhat superior and outside 
from the position viewing conventional parasternal short axis image of 
the aortic valve, angle between LA appendage midline and   Doppler 
beam narrowed.  The LAA was carefully sought and visualized on the left 
side of the aorta and on the right inferior side of main pulmonary trunk.  
The left atrial appendage flow velocity was recorded by pulsed Doppler 
Echocardiography with sampling volume placed at the left atrial 
appendage orifice 
Sample Collection. 
              Blood samples were obtained between 7:00 and 9:00am, after an 
overnight fast and at least a 20-min rest period, from the antecubital vein 
of the patients.  Samples were transported to the laboratory at room 
temperature within 45 min after venipuncture.  Sodium citrate solution 
(0.2ml) was mixed with 1.8ml of venous blood and centrifuged for 10min 
at 3,500 r.p.m.  The plasma (as supernatant) was removed at + 15C, and 
the results were measured using a commercial particle enhanced 
immunoturbidimetry.  The intra – and inter- assay coefficients variation 
were less than 4%.  Normal plasma levels of D-dimer range from 0 to 0.4 
µgm FEU/ml 
Statistical Analysis  
  All statistical analyses were conducted using SPSS version 16.0 
for windows.  The results were analyzed with descriptive statistical 
methods (mean+SD), as the D- dimer levels were found to   be normally 
distributed .  The numbers were rounded to the nearest integral for data 
presentation.  Differences between groups were analyzed using student t 
test to analyse and compare two means, descriptive data were used for 
chi-square analysis. And significant differences were found between the 
subgroups.  A p-value <0.05 was considered to be statistically significant. 
 
 
 
RESULTS AND ANALYSIS 
The mean age of the 65 study patients was 34± 10. 
 And Atrial fibrillation was present in 17% of the study population. 
The samples are subdivided into various sub groups based on the patients 
heart rhythm and valvular pathology.  
The highest D-dimer levels were present in the MS +MR+ AF 
subgroup, lowest levels of are found in MR+ SR subgroup 
 Males comprised 26 (40%) and female 39 (60%) of the total. 
Majority 54 (83.08 %) of the sample were NSR and  11 (16.92 %) were 
in AF. The distribution between Gender and AF were not differed 
statistically.  
Majority among females 33 (84.62%) of them having MS while 
comparing males 15 (57.69 %). The distribution between Gender and MS 
differed statistically (P <0.02). 
 
Table-1 
Age distribution of the Sample  
Age Group Male Female Total 
No of  
Patient 
% No of 
Patients 
% No of 
Patients 
% 
< 20 3 11.54 2   5.13 5   7.69 
21- 30 10 38.46 15 38.46 25 38.46 
31 -40 6 23.08 8 20.51 14 21.54 
41–50 7 26.92 13 33.33 20 30.77 
51-60 0 0 1   2.56 1   1.54 
Total 26 100 39 100 65 100 
Mean ± Sd 32.19 ± 9.30 35.05 ± 10.25 33.91 ± 9.91 
 t=1.14 df=63 Not Significant   
Patients were distributed across the age spectrum of 14 to 54 years. 
Mean age of the patients was 33.91 ± 9.91 (male 32.19 ± 9.30 and female 
35.05 ± 10.25) years. Most patients (n=25) were in the age group of 21-
30 years. Youngest patient was 14 years old. 
 
 
 
 
 
  
 
0
5
10
15
20
25
< 20 21- 30 31 -40 41–50 51-60
Male Female
Age Distribution of  the Study Sample 
Table-2 
Weight & Height 
 Male Female Total Significant 
(Male Vs Female) Mean ± sd Mean ± sd Mean ± sd 
Weight  (Kg)   56.42 ±  
7.40 
  51.90 ± 
8.18 
 53.71 ± 
8.13 
t=2.27 df=63 P<0.03 
Height  (Cm) 160.15 ±  
3.48 
153.31 ± 
6.37 
156.05 ± 
6.34  
t=5.00 df=63 
P<0.0001 
 
Sd= Standard Deviation   NS – Not Significant  
The above table reveals that males had high Weight (male 56.42 ± 
7.40),   female (51.90 ± 8.18) and Height (male 160.15 ± 3.48 and female 
153.31 ± 6.37) than females. The t-value reveals that there is significant 
association between Weight (P<0.03) with Gender and Significant 
association between Gender with Height (P<0.0001) 
 
 
 
 
Table-3 
ATRIAL FIBRILATION  
 Male Female Total 
No of  
Patient 
% No of 
Patients 
% No of 
Patients 
% 
AF 5 19.23  6 15.38  11  16.92  
NSR 21 80.77 33 84.62 54 83.08 
Total 26 100 39 100 65 100 
 Chi square =1.16 df=1  NS   
 
Males comprised 26 (40%) and female 39 (60%) of the total. 
Majority 54 (83.08 %) of the sample were NSR and 11 (16.92 %) were 
AF. The distribution between Gender and ECG were not differed 
statistically. 
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Table-4 
LA Dimension  
 Male Female Total Significant 
(Male Vs Female) Mean ± sd Mean ± sd Mean ± sd 
LA Dimension 
In cm. 
   4.24 ±  0.89   4.25 ± 
0.67 
 4.24 ±  0.76 t=0.04  df=63 NS 
 
Sd= Standard Deviation   NS – Not Significant  
 The above table shows LA Dimension. Mean LA Dimension 
between Genders were not differed statistically. 
Most of the patients with rheumatic heart disease with mitral valve 
involvement showed LA size in the mean range of 4.24±0.76.  
Also it is found there is no age correlation of AF in RHD patients 
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Table-5 
MS 
 Male Female Total 
N % N % N % 
Not Present 11 42.31 6 15.38 17 26.15 
Present 15 57.69 33 84.62 39 73.85 
 Chi square =5.86 df=1  p 
<0.02 
  
 
Majority of females 33 (84.62%) have MS while comparing males 
15 (57.69 %). The distribution between Gender and MS differed 
statistically (P <0.02). 
 
 
 
 
 
 
 
TABLE-6 
MR 
 Male Female Total 
N % N % N % 
Not Present  10 38.46 20 51.28 30 46.15 
Present 16 61.54 19 48.72 35 53.85 
Total 26 100 39 100 65 100 
 Chi square =1.03 df=1  NS   
 
Above table reveals MR status of the Gender. From the above we 
can say presence of MR is higher in Males 16 (61.54%) then females 19 
(48.72%). The difference is statistically not significant.  
 
 
 
 
 
 
 
TABEL-7 
AR 
 Male Female Total 
N % N % N % 
Not Present 18 69.23 21 53.85 39 60.00 
Present 8 30.77 18 46.15 26 40.00 
Total 26 100 39 100 65 100 
 Chi square =1.54 df=1  NS   
 
 The above table reveals AR is seen in both the gender but more in 
females. Difference between gender is statistically not significant.  
 
 
 
 
 
 
 
 
TABLE-8 
Pul HT 
 Male Female Total 
N % N % N % 
Not Present  14 53.85 12 30.77 26 40.00 
Present 12 46.15 27 69.33 39 60.00 
Total 26 100 39 100 65 100 
 Chi square =3.46 df=1   NS   
 
From the above table it is observed the females are more prone to 
develop Pul HT among RHD patients. Difference in PulHT between 
gender is statistically not significant.    
 
 
 
 
 
 
 
TABLE-9 
CORRELATION OF AF AND SR TO LAA VELOCITY, 
LA DIMENSION AND D-DIMER LEVEL 
Variable AF 
N=11 
NSR  
N=54 
t-value 
 
Df significant 
Age ( in Years) 34.82 ±  
6.52 
33.72 ± 
10.50 
0.33
t
 63 NS 
LAA Velocity 40.55 ±  
2.84 
45.50 ±  
8.10 
1.99
 t
 63     P< 0.05 
LA Dimension  4.81 ±  
0.99 
4.13 ±  0.66 2.58
 t
 63     P< 0.01 
D-dimer  0.50 ±  0.47 0.28 ±  0.14 5.06
 t
 63 P< 0.001 
NS-Not significant t– T-value  
While comparing AF patient and SR patients; LAA velocity is 
lower in AF group of patients then SR group of patients, the difference is 
statistically significant (p<0.05); LA dimension is higher in AF  patients 
then SR patients, the difference is statistically significant ( p <0.01).; in 
D-dimer level in AF patients are having higher than the SR patients, the 
difference  is statistically significant ( p <0.001)    
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TABLE-10 
CORRELATION OF MS+AF AND MS+SR TO LAA 
VELOCITY, LA DIMENSION AND D-DIMER LEVEL 
Variable MS+AF 
N=11 
MS+SR  
N=37 
t-value 
 
Df significant 
Age ( in Years) 34.82 ±  6.52 35.62 ± 10.87 0.23
t
 46 NS 
LAA Velocity 40.55 ±  2.84 43.86 ±  9.08 1.18
 t
 46 NS 
LA Dimension  4.81 ±  0.99 4.27 ±  0.67 2.09
 t
 46 P< 0.04 
D-dimer  0.50 ±  0.47 0.30 ±  0.15 2.27
 t
 46 P< 0.03 
 
While comparing MS+AF patient and MS+SR patients; LAA 
velocityy is lower in MS+AF group of patients then MS+SR group of 
patients, the difference is not statistically significant; LA dimension size 
is higher in MS+AF patients then MS+SR patients, the difference is 
statistically significant (p<0.04).; in D-dimer score MS+AF patients are 
having higher level than the MS+SR patients, the difference is 
statistically significant ( p <0.03).    
 
 
TABLE-11 
 CORRELATION OF MR+AF AND MR+SR TO LAA 
VELOCITY, LA DIMENSION AND D-DIMER LEVEL 
Variable MR+AF 
N=6 
MR+SR  
N=29 
t-value 
 
Df significant 
Age ( in Years) 34.33 ±  6.80 29.03 ± 9.54 0.60
t
 33 NS 
LAA Velocity 40.00 ±  1.26 47.55 ± 4.66  0.87
 t
 33 NS 
LA Dimension  5.18 ±  0.93 4.01 ±  0.63 1.65
 t
 33 NS 
D-dimer  0.52 ±  0.05 0.26 ±  0.13 1.94
 t
 33 NS 
 
The above table reveals MR associated with SR, the D-dimer levels 
are comparatively lower than when associated with AF. 
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TABLE-12 
CORRELATION OF MS+MR+AF AND MS+MR+SR TO 
LAA VELOCITY, LA DIMENSION AND D-DIMER 
LEVEL 
Variable MSMR+AF 
N=5 
MSMR+SR  
N=15 
t-value 
 
Df significant 
Age ( in Years) 35.20 ±  7.23 29.73 ± 10.51 1.07
t
 18 NS 
LAA Velocity 40.40 ±  0.89 45.07 ± 5.20  1.96
 t
 18 P<0.05 
LA Dimension  5.24 ± 1.03 4.29 ±  0.97 1.87
 t
 18 NS 
D-dimer  0.53 ±  0.04 0.30 ±  0.17 2.95
 t
 18 P<0.01 
 
From the above table shows that LAA Velocity is significantly 
differ in MSMR+AF than the MSMR+SR patients (p <0.05).  D-dimer 
level is shows statistically significant difference between MSMR+AF and 
MSMR+SR (P <0.01).    
 
 
 
TABLE-13 
CORRELATION OF MS+MR+AR+AF AND MS+MR+ AR+SR 
TO LAA VELOCITY, LA SIZE AND D-DIMER LEVEL 
 
Variable MSMRAR+AF 
N=4 
MSMRAR+SR  
N=5 
t-value 
 
Df significa
nt 
Age ( in Years) 36.25 ±7.89 34.60 ±13.43 0.22 7 NS 
LAA Velocity 40.50 ±1.00 46.60 ±8.02  1.49 7 NS  
LA Dimension  5.50±0.98 4.34 ± 0.75   2.02 7 NS 
D-dimer  0.53± 0.05 0.27 ±  0.20 2.51 7 P< 0.05 
 
Association of AR to mitral stenosis and regurgitation lesion does not 
make much difference 
 
 
 
 
DISCUSSION 
In this study, an investigation was made into “RHD” patients with 
various subsets with or without rhythm disturbances with plasma D-dimer 
levels. And its correlation also done to other variables to LA linear 
dimension and LAA contraction velocity.  
 It was analysed that plasma D-dimer levels were significantly 
higher in patients “RHD” with MS with AF group and significantly lower 
in “RHD” with MR with SR group .But when associated with MR the 
results are equivocal.   
 The results of the present study supported the hypothesis that 
severe MR decreases coagulation activity and thrombus formation in the 
left atrium of patients with AF or MS by increasing the shear stress on the 
left atrial wall, and creating a high-flow wash-out jet which inhibits 
thrombogenesis on a mechanical basis.  
 Plasma D-dimer levels provide a sensitive assay for monitoring 
this process.  Plasma D-dimer levels reflect abnormal intra atrial wall, 
and creating a high-flow wash-out jet which inhibits thrombogenesis on a 
mechanical basis.  Plasma D-dimer levels provide a sensitive assay for 
monitoring this process.  Plasma D-dimer levels reflect abnormal intra 
atrial hemodynamics and also the risk of clotting.  
 Both, AF and MS, cause the stagnation of blood in the left atrium 
and activate the coagulation system.  This in turn cause intra cardiac SEC 
formation and /or thrombus formation and a decreased blood flow 
velocity.  These hemodynamic events increase the plasma levels of D-
dimer, tissue plasminogen activator inhibitor-1 and von Willebrand factor 
in the peripheral circulation. 
Sample implies most of the patients are in middle aged and among 
them female and male ratio is not   statistically significant. Added that 
sample less than 20 yrs old is only 7%. The Atrial fibrillation was present 
in 17% of individuals in our study. 
 In Isolated MS various study showed AF prevalence of 20 to 40%. 
In Isolated MR prevalence is 15 to 30%. In this study atrial fibrillation 
found in both sexes is not statistically significant. Chang et.al found that 
there was no difference in frequency of AF with reference to sex. 
Nadeem et.al, showed some difference.  
The study also showed that LA dimension is increased in all the 
samples with mitral valve involvement with a mean value of 4.24 ± 0.76. 
Normal LA dimension for age adjusted value is 1.8 to 4 cm (3.1 ± 0.5 
cm) by Hirata et.al., and Brown et.al., showed 2.3 to 4.4 cm and showed a 
linear correlations to age and dimension. 
When AF present in the sample it is observed there is increased LA 
size and decreased LAA velocity noted. Correspondingly plasma D-dimer 
level noted more than 0.45 microgram FEU/ml in these patients which is 
statistically significant. 
 Like wise it is observed mitral stenotic patients when associated 
with AF showed increased LA size and decreased LAA velocity and 
increased plasma D-dimer level which are statistically significant. In this 
study highest level are found in the MS+MR+AF subset of patients 
comparing other groups and lower levels are found in MR+SR group. 
        
STUDY LIMITATIONS 
 The primary limitation was the small number of patients in each 
group, which limited the statistical power of the study. 
 Second, TTE cannot exclude the presence of small thrombi which 
might affect D-dimer levels; hence, TEE might have been a useful 
addition for measuring left atrial appendage velocities, the prevalence of 
the SEC, and thrombus formation.  
Third, although D-dimer levels reflect the extent of the thrombotic 
state very well, other markers (e.g. fibrinogen, PAI-1, / tPA) would have 
improved the analysis of these patients. 
 Fourth, a turbidimetric test was used for plasma D-dimer 
assessments in this study. Although ELISA-based D-dimer assays are 
considered the „gold standard‟, others have shown that selected latex 
turbidimetric assays produce results comparable to those with ELISA and 
the present results can be considered valid.  
Although Rudnicka et.al reported a 10% diurnal variation D-dimer 
levels in a cohort of 9,377 men and women aged 45 years. In the present 
study all blood samples were obtained during the early morning. No 
power calculations were performed. 
 Finally, although a through history and physical examination was 
carried out on each study participant to rule out deep venous 
thromboembolism, the subjects were not screened by Doppler 
examination. It is difficult, however, even with Doppler, to rule out 
subclinical venous thromboembolic disease in these patients.  
Despite these limitations, the study merits attention, notably as a 
direct comparison among patient groups with various sub types of mitral 
valve disease associated with rhythm disturbances and aortic valve 
involvement.  
CONCLUSION 
 RHD is one among the cause to give more morbidity and 
mortality in the developing countries.  
 Presence of Atrial fibrillation worsen the situation as it may 
lead to more thromboembolic manifestation than age matched controls. 
 Added the variables in the study like increased LA size and 
decreased LAA velocity increase the risk of thrombus formation among 
the subsets of RHD patients. 
 The presence of moderate to severe MR reduces the risk of 
thromboembolic manifestation as evidenced by decreased plasma D-imer 
level in these subsets of these patients indicating systemic 
hypofibrinolytic state. 
 In the subset MS+MR+AF association predict a greatest risk 
among the RHD patients inspite of MR for thromboembolism.  
 It was concluded that plasma D-dimer level in these patients 
can predict thromboembolic risk to some extent. 
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PROFORMA 
Serial No:     Date: 
Name:    Age:   Sex:   Wt 
Address: 
Diagnosis: 
ECG:  NSR/AF 
Any Medication: 
Co Morbidity 
 
Personal H/O   Smoker   Alcoholic 
 
ECHO   LA Dimension   Echo Auto Contest 
LA Clot    LAAVelocity 
MS Severity     MVO    Mild  Mod          
Severe 
MR Severity      Mild  Mod            
Severe 
AS       AR 
LVEF%   Pul HT  TR Velocity 
D-dimer Level   

MASTER CHART 
IDNO Name Age SEX WEIGHT HEIGHT ECG 
LA 
DIMENSION 
cm 
LAA 
VELOCITY 
cm/sec MVO MS MR AS AR LV PUL_HT 
D_DIMER 
µgm/ml-
FEU 
1 RAJASEKARAN 21 M 52 160 NSR 3.80 53.00 2.80 NIL Severe NIL NIL N Mild 0.31 
2 DHINESH GOWSIK 15 M 48 156 NSR 4.60 51.00 1.80 Mild Severe NIL Severe N Mild 0.09 
3 GEETHA 27 F 50 158 NSR 3.50 45.00 3.10 NIL Mild NIL Mild N Mild 0.30 
4 PUSHPA 40 F 59 151 AF 5.70 42.00 0.90 Severe Mild Mild Mild N Mild 0.48 
5 ARUNACHALAM 46 M 58 165 AF 6.00 40.00 1.10 Mod NIL NIL NIL N Mod 0.50 
6 BHASKER 26 M 68 158 NSR 4.30 42.00 3.10 NIL Mild NIL NIL N NIL 0.54 
7 GOWRI 50 F 62 163 NSR 4.30 50.00 1.80 Mild NIL NIL Mod N Mild 0.13 
8 GOMALA 45 F 39 140 NSR 5.60 42.00 0.70 Severe NIL Severe Mod N Mild 0.34 
9 ANJAMMAL 44 F 55 154 NSR 4.50 54.00 1.30 Mod NIL Severe Mod N Mild 0.32 
10 MAHESH 27 M 60 158 NSR 4.80 50.00 1.80 Mild NIL NIL NIL N NIL 0.20 
11 MUTHULAKSHMI 27 F 41 144 NSR 5.10 38.00 1.10 Mod Mild NIL Mild N Mild 0.32 
12 KANNAGI 19 F 48 154 NSR 3.60 48.00 1.90 Mild Mild NIL NIL N NIL 0.12 
13 MARIAMMAL 45 F 66 154 NSR 4.40 38.00 1.30 Mod NIL NIL Mod N Mild 0.52 
14 PRABHAGAR 31 M 60 162 NSR 4.40 50.00 2.80 NIL Mild NIL NIL N NIL 0.24 
15 BALA 26 F 40 144 NSR 4.80 48.00 0.90 Severe Mild NIL NIL N Mild 0.09 
16 MURALI 19 M 52 161 NSR 3.80 48.00 1.90 Mild Mild NIL NIL N NIL 0.29 
17 THIRUVENGADAM 45 M 45 167 AF 6.80 40.00 1.30 Mod Severe NIL Mild N Severe 0.52 
18 PARIMALA 23 F 54 156 NSR 4.30 52.00 1.70 Mild Mod NIL NIL N Mild 0.42 
19 LATHA 40 F 52 157 NSR 4.80 38.00 1.40 Mod Mild Mod Mod N Mod 0.58 
20 salini 32 F 55 154 AF 4.00 42.00 1.30 Mod NIL NIL NIL N Mild 0.52 
21 SHOBA 18 F 50 149 NSR 3.20 55.00 3.10 NIL Mod NIL NIL N NIL 0.41 
22 PRAKASH 30 M 60 155 NSR 4.20 52.00 3.10 NIL Mild NIL NIL N NIL 0.13 
23 RAMANI 26 F 60 158 NSR 3.80 40.00 1.40 Mod NIL NIL NIL N NIL 0.25 
24 THILAGAM 49 F 58 164 NSR 3.30 46.00 1.80 Mild NIL Mild Mod N Mild 0.32 
25 VIJAYALAKSHMI 36 F 49 161 NSR 4.50 45.00 1.00 Severe NIL Mod Mild N Severe 0.38 
26 LOKESH 27 M 51 158 NSR 4.00 42.00 1.70 Mild NIL NIL NIL N Mild 0.42 
27 NASREEN 28 F 49 152 NSR 5.10 40.00 2.10 Mild Mod NIL NIL N NIL 0.19 
28 RAJAN 39 M 51 158 NSR 3.60 44.00 1.80 Mild Mild NIL NIL N Mild 0.32 
29 SARAVANAN 33 M 48 161 AF 4.90 40.00 1.00 Severe Mod NIL Mod N Mod 0.60 
30 VIDYA 29 F 55 160 NSR 4.20 48.00 2.80 NIL Mod NIL NIL N NIL 0.14 
31 VIGNESWARI 54 F 60 156 NSR 4.20 51.00 1.80 Mild NIL NIL NIL N NIL 0.21 
32 RAJU 38 F 48 158 NSR 3.80 36.00 0.90 Severe NIL NIL NIL N Mod 0.48 
33 SELVI 48 F 52 140 NSR 3.20 51.00 1.80 Mild Mild NIL Mild N Mod 0.23 
34 SOMU 42 M 61 159 NSR 3.90 50.00 2.90 NIL Mild NIL NIL N NIL 0.26 
35 SIVAN 30 M 50 163 NSR 3.60 52.00 3.20 NIL NIL NIL Mild N NIL 0.14 
36 JERINA 22 F 38 148 NSR 3.20 49.00 1.90 Mild Mild NIL NIL N NIL 0.18 
37 VALLI 26 F 60 152 NSR 3.80 46.00 2.80 NIL Mild NIL NIL N NIL 0.31 
38 CHELLAMAL 45 F 55 155 NSR 5.10 45.00 3.10 NIL Severe NIL NIL N NIL 0.13 
39 PANDURENGAN 30 M 60 161 AF 4.90 38.00 1.20 Mod Mild NIL NIL N Mild 0.45 
40 LALITHA 27 F 55 159 AF 4.60 40.00 0.90 Severe Mild NIL Mild N Mod 0.52 
41 SUNDARI 42 F 54 148 NSR 3.80 54.00 1.90 Mild NIL NIL NIL N NIL 0.21 
42 KUMAR 43 M 66 159 NSR 4.00 55.00 1.45 Mod Mild NIL Mild N Mild 0.13 
43 GOMATHI 28 F 48 157 AF 4.30 38.00 1.40 Mod NIL NIL Mild N Mod 0.42 
44 REVENAIAH 42 M 51 162 NSR 4.00 40.00 1.30 Mod Mild NIL NIL N Mod 0.45 
45 PURUSHOTH 33 M 67 162 NSR 3.80 34.00 1.10 Mod NIL NIL NIL N NIL 0.03 
46 KALAI 23 F 49 153 NSR 4.20 38.00 0.90 Severe NIL NIL NIL N Mod 0.52 
47 JAIGANESH 40 M 65 162 NSR 3.20 50.00 3.10 NIL NIL NIL Mild N NIL 0.13 
48 KAMESH 26 M 64 160 NSR 3.20 46.00 2.80 NIL Mod NIL Mild N NIL 0.23 
49 RAMU 38 F 45 161 AF 3.70 48.00 0.80 Severe NIL NIL NIL N Mod 0.48 
50 SHANKER 14 M 43 150 NSR 3.10 52.00 3.20 NIL Mild NIL NIL N NIL 0.32 
51 VALARMATHI 31 F 44 152 AF 4.20 40.00 1.20 Mod Mild NIL NIL N Mod 0.53 
52 ARUNACHALAM 46 M 58 165 NSR 6.00 4.00 1.10 Mod NIL NIL NIL N Mod 0.30 
53 SOMU 42 M 61 159 NSR 3.90 50.00 2.90 NIL Mild NIL NIL N NIL 0.26 
54 PURUSHOTH 33 M 67 162 AF 3.80 38.00 1.10 Mod NIL NIL NIL N NIL 0.50 
55 LOKESH 27 M 51 158 NSR 4.00 42.00 1.70 Mild NIL NIL NIL N Mild 0.42 
56 RAJESHWARI 50 F 62 163 NSR 4.30 50.00 1.80 Mild NIL NIL Mod N Mild 0.13 
57 ANURADHA 44 F 55 154 NSR 4.50 54.00 1.30 Mod NIL Severe Mod N Mild 0.32 
58 BALACHANDRAN 26 F 40 144 NSR 4.80 48.00 0.90 Severe Mild NIL NIL N Mild 0.09 
59 MUNIAMMA 45 F 66 154 NSR 4.40 38.00 1.30 Mod NIL NIL Mod N Mild 0.52 
50 KAMALA 45 F 39 140 NSR 5.60 42.00 0.70 Severe NIL Severe Mod N Mild 0.34 
61 RANJU 38 F 48 158 NSR 3.80 36.00 0.90 Severe NIL NIL NIL N Mod 0.48 
62 SIVARAJAN 30 M 50 163 NSR 3.60 52.00 3.20 NIL NIL NIL Mild N NIL 0.14 
63 JASMINE 22 F 38 148 NSR 3.20 49.00 1.90 Mild Mild NIL NIL N NIL 0.18 
64 MALLIGA 26 F 60 152 NSR 3.80 46.00 2.80 NIL Mild NIL NIL N NIL 0.31 
65 DHANALAKSHMI 45 F 66 154 NSR 4.40 38.00 1.30 Mod NIL NIL Mod N Mild 0.52 
 
 
                                  ABSTRACT 
 
Assessment of Prothrombotic Burden in the Rheumatic  
heart disease with various subset   
 
    Background : RHD is more common in middle aged in 
dividuals with stroke manifestation . Among  the subset of 
patients with RHD it is more commonly associated in  MS 
with AF patients.  And it is more common when increased  
LA Size as well as decreaesd LAA empting Velocity.  So 
our study evaluated the correlation 
 Method.  Blood sample collected to this patients with 
RHD with excluding older age, H/o surgery and DVTand  
Recent trauma.  D-dimer assayed   by particle enhanced 
immunoturbidimetry.   Echo done to all patients.  
 
     Results: It was analysed that age distribution is in the 
range of 33.91to 9.91.With AF Association present in 
16.92% of the  Individual.  Mean LA dimension in all 
subsets in the range of 4.47+ 0.82.   D-dimer level is 
highest in the subset of MS + MR + AF subgroup  0.53+ 
0.04 µgm FEU/ ml. 
   Conclusion:  It was concluded the highest D-dimer level 
found in MS+MR+AF group and lower in MS+SR group. 
Presensce of MR dose not prevent thromboembolism when 
associated   With AF and MS. 
 
 
 
 
 
